Arrhythmias & electrophysiology
Stereotactic arrhythmia radioablation for refractory ventricular tachycardia—The initial Australian experience
Authors' conclusion
This paper summarizes the initial Australian experience treating refractory VT with STAR. It demonstrates that STAR can significantly decrease the VT and VT storm burden during a 6-month follow-up with an acceptable acute adverse effect profile, albeit with a high VT recurrence rate.
Study context
- Population
- Patients with drug-refractory ventricular tachycardia (VT) for whom catheter ablation had failed or who were unsuitable for it9 survived the blanking period
- Participants
- 12 patients
- Exposure
- 6 months before vs after stereotactic arrhythmia radioablation (STAR)
- STARn = 12
- Outcome
- VT burden
- Follow-up
- 6-month follow-up
Methodological details2 Australian centers
- 2 Australian centers
Main finding
As reported in the abstract
- Reduction
- 64.5%
- P
- P = .011
Observational data: associations, not effects.
Further findings
VT storm · 6-month follow-up
- Reduction
- 71.7%
- P
- P = 0.027
VT recurrence
- Patients with VT recurrence
- 66.7% (6/9)
- Of 6 patients with recurrence with ECGs available, same VT morphology as before STAR
- 3
Safety
Mortality and adverse events · 12-month follow-up
- Deaths
- 5
- Adverse events (undersensing of defibrillator lead, increased rate of reflux, and radiation pneumonitis)
- 3
Original publication
Stereotactic arrhythmia radioablation for refractory ventricular tachycardia—The initial Australian experience. Heart Rhythm. Published 6 February 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →